[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601521":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":19,"locations":25,"responsibleParty":42,"collaborators":46,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":59,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":10,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":77,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Qilu Hospital of Shandong University","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"UC patients accept therapy of biologics",null,[12],"Diagnostic Test: fecal calprotectin",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DIAGNOSTIC_TEST","fecal calprotectin","patients will accpet test of FC combine FIT",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Yan Zhang, M.D","CONTACT","+86 18560089821","qlzhangyan@sdu.edu.cn",[26],{"facility":5,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"RECRUITING","Jinan","Shandong","251400","China","CN",{"type":34,"coordinates":35},"Point",[36,37],116.99722,36.66833,{"lat":37,"lon":36},[40],{"name":41,"role":22,"phone":23,"phoneExt":10,"email":24},"Yan Zhang, M.D.",{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Yan Zhang, MD","M.D",[47,49,51,53,55],{"name":48,"class":6},"Qilu Hospital of Shandong University (Qingdao)",{"name":50,"class":6},"Dezhou Hospital Qilu Hospital of Shandong University",{"name":52,"class":6},"Weihai Municipal Hospital",{"name":54,"class":6},"Liaocheng People's Hospital",{"name":56,"class":6},"Jining First People's Hospital","100601521","fecal-biomarker-response-evaluation-for-super-early-efficacy-in-ulcerative-colitis-100601521",false,"NCT07111572","Fecal biOmarker Response Evaluation for Super-Early Efficacy in Ulcerative Colitis","Dynamic Changes of Fecal Calprotectin and Fecal Immunochemical Test for Early Prediction of Biologic Treatment Efficacy in Ulcerative Colitis: A Multicenter, Prospective Cohort Study","FORESEE-UC","Inclusion Criteria:\\*\\*\n\n* Age 18-75 years, UC diagnosis with endoscopic Mayo score (MES) ≥2\n* Moderate-to-severe activity (Full Mayo Score ≥6)\n* Initiating vedolizumab or infliximab within 7 days after baseline\n* Biologic-naïve or prior exposure to only one TNF-α inhibitor\n\n\\*\\*Exclusion Criteria:\\*\\*\n\n* Pregnancy\u002Flactation\n* Contraindications to biologics (e.g., active TB, severe infection)\n* Experimental drug use within 4 weeks prior to baseline","ALL","18 Years","75 Years",{"count":69,"type":70},100,"ESTIMATED","OBSERVATIONAL","This multicenter prospective cohort aims to evaluate whether combined changes in fecal calprotectin (FC) and fecal immunochemical test (FIT) at \\*\\*Week 2 and Week 4\\*\\* after initiating biologic therapy (vedolizumab or infliximab) can predict clinical response at \\*\\*Week 14\\*\\* and mucosal healing at \\*\\*Week 52\\*\\* in moderate-to-severe ulcerative colitis (UC) patients. Primary outcome: clinical remission rate at Week 14.",[74,75,76],"Ulcerative Colitis (UC)","Fecal Calprotetin","FIT",[78,16,76],"UC","2026-07-27",{"date":81,"type":82},"2026-07-28","ACTUAL",{"date":84,"type":82},"2025-08-01",{"date":86,"type":70},"2026-12-01",{"name":5,"class":6},1]